277 related articles for article (PubMed ID: 28004853)
21. Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
Liefferinckx C; Verstockt B; Gils A; Noman M; Van Kemseke C; Macken E; De Vos M; Van Moerkercke W; Rahier JF; Bossuyt P; Dutré J; Humblet E; Staessen D; Peeters H; Van Hootegem P; Louis E; Franchimont D; Baert F; Vermeire S;
J Crohns Colitis; 2019 Oct; 13(11):1401-1409. PubMed ID: 30989232
[TBL] [Abstract][Full Text] [Related]
22. Ustekinumab Improves Active Crohn's Disease by Suppressing the T Helper 17 Pathway.
Ihara Y; Torisu T; Miyawaki K; Umeno J; Kawasaki K; Hirano A; Fujioka S; Fuyuno Y; Matsuno Y; Sugio T; Sasaki K; Moriyama T; Akashi K; Kitazono T
Digestion; 2021; 102(6):946-955. PubMed ID: 34350861
[TBL] [Abstract][Full Text] [Related]
23. Management of Paediatric Patients With Medically Refractory Crohn's Disease Using Ustekinumab: A Multi-Centred Cohort Study.
Chavannes M; Martinez-Vinson C; Hart L; Kaniki N; Chao CY; Lawrence S; Jacobson K; Hugot JP; Viala J; Deslandres C; Jantchou P; Seidman EG
J Crohns Colitis; 2019 Apr; 13(5):578-584. PubMed ID: 30541021
[TBL] [Abstract][Full Text] [Related]
24. Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's disease.
Derikx LAAP; Plevris N; Su S; Gros B; Lyons M; Siakavellas SI; Constantine-Cooke N; Jenkinson P; O'Hare C; Noble C; Arnott ID; Jones GR; Lees CW
Dig Liver Dis; 2023 Aug; 55(8):1034-1041. PubMed ID: 36283944
[TBL] [Abstract][Full Text] [Related]
25. Predictive models assessing the response to ustekinumab highlight the value of therapeutic drug monitoring in Crohn's disease.
Liefferinckx C; Hubert A; Thomas D; Bottieau J; Minsart C; Cremer A; Amininejad L; Vallée F; Toubeau JF; Franchimont D
Dig Liver Dis; 2023 Mar; 55(3):366-372. PubMed ID: 35977875
[TBL] [Abstract][Full Text] [Related]
26. Multimodal dynamic ultrasound approach as predictor of response in patients with Crohn's disease treated with ustekinumab.
Ainora ME; Liguori A; Mignini I; Cintoni M; Galasso L; Laterza L; Lopetuso LR; Garcovich M; Riccardi L; Gasbarrini A; Scaldaferri F; Zocco MA
Therap Adv Gastroenterol; 2024; 17():17562848241259289. PubMed ID: 38912296
[TBL] [Abstract][Full Text] [Related]
27. Ustekinumab Tissue and Serum Levels in Patients With Crohn's Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction.
Proietti E; Pauwels RWM; van der Woude CJ; Doukas M; Oudijk L; Peppelenbosch MP; Grohmann U; Crombag MBS; de Vries AC; Fuhler GM
Inflamm Bowel Dis; 2023 Jul; 29(7):1038-1046. PubMed ID: 35917118
[TBL] [Abstract][Full Text] [Related]
28. Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study.
Yanai H; Kagramanova A; Knyazev O; Sabino J; Haenen S; Mantzaris GJ; Mountaki K; Armuzzi A; Pugliese D; Furfaro F; Fiorino G; Drobne D; Kurent T; Yassin S; Maharshak N; Castiglione F; de Sire R; Nardone OM; Farkas K; Molnar T; Krznaric Z; Brinar M; Chashkova E; Livne Margolin M; Kopylov U; Bezzio C; Bar-Gil Shitrit A; Lukas M; Chaparro M; Truyens M; Nancey S; Lobaton T; Gisbert JP; Saibeni S; Bacsúr P; Bossuyt P; Schulberg J; Hoentjen F; Viganò C; Palermo A; Torres J; Revés J; Karmiris K; Velegraki M; Savarino E; Markopoulos P; Tsironi E; Ellul P; Calviño Suárez C; Weisshof R; Ben-Hur D; Naftali T; Eriksson C; Koutroubakis IE; Foteinogiannopoulou K; Limdi JK; Liu E; Surís G; Calabrese E; Zorzi F; Filip R; Ribaldone DG; Snir Y; Goren I; Banai-Eran H; Broytman Y; Amir Barak H; Avni-Biron I; Ollech JE; Dotan I; Aharoni Golan M
J Crohns Colitis; 2022 Dec; 16(12):1882-1892. PubMed ID: 35895074
[TBL] [Abstract][Full Text] [Related]
29. Ustekinumab Drug Levels in Maternal and Cord Blood in a Woman With Crohn's Disease Treated Until 33 Weeks of Gestation.
Rowan CR; Cullen G; Mulcahy HE; Keegan D; Byrne K; Murphy DJ; Sheridan J; Doherty GA
J Crohns Colitis; 2018 Feb; 12(3):376-378. PubMed ID: 29045603
[TBL] [Abstract][Full Text] [Related]
30. Systematic Review and Meta-Analysis: Association between Preoperative Ustekinumab and Surgical Complications in Crohn's Disease Patients.
Li L; Jiang K; Lou D; Zhang M; Shi Y; Shen J; Fu X
Eur Surg Res; 2023; 64(4):412-421. PubMed ID: 37598662
[TBL] [Abstract][Full Text] [Related]
31. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
32. Dual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Crohn's Disease.
Miyatani Y; Choi D; Choi NK; Rubin DT
Dig Dis Sci; 2024 Feb; 69(2):355-359. PubMed ID: 38112840
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence.
Engel T; Yung DE; Ma C; Pariente B; WIls P; Eliakim R; Ungar B; Ben-Horin S; Kopylov U
Dig Liver Dis; 2019 Sep; 51(9):1232-1240. PubMed ID: 31202609
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study.
Rayer C; Nachury M; Bourreille A; Roblin X; Peyrin-Biroulet L; Viennot S; Flamant M; Laharie D; Caron B; Dewitte M; Siproudhis L; Fumery M; Bouguen G
BMC Gastroenterol; 2022 Dec; 22(1):498. PubMed ID: 36457080
[TBL] [Abstract][Full Text] [Related]
35. Efficacies and Related Issues of Ustekinumab in Japanese Patients with Crohn's Disease: A Preliminary Study.
Miyazaki T; Watanabe K; Kojima K; Koshiba R; Fujimoto K; Sato T; Kawai M; Kamikozuru K; Yokoyama Y; Hida N; Nakamura S
Digestion; 2020; 101(1):53-59. PubMed ID: 31722356
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
Aliyev ER; Hay JW; Hwang C
Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
[TBL] [Abstract][Full Text] [Related]
37. Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn's disease: results from a large Italian cohort study.
Tursi A; Mocci G; Cuomo A; Allegretta L; Aragona G; Colucci R; Della Valle N; Ferronato A; Forti G; Gaiani F; Graziani MG; Lorenzetti R; Luzza F; Paese P; Penna A; Pica R; Piergallini S; Pranzo G; Rodino S; Scarcelli A; Zampaletta C; Cicerone C; Cocco A; De' Angelis G; Donnarumma L; Franceschi M; Gallina S; Grasso G; Larussa T; Luppino I; Faggiani R; Fanigliulo L; Pagnini C; Perazzo P; Sacco R; Sebkova L; Scorza S; Serio M; De Monti A; Picchio M; Elisei W; Maconi G
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(4):2099-2108. PubMed ID: 33660823
[TBL] [Abstract][Full Text] [Related]
38. Intravenous Ustekinumab Reinduction Is Effective in Prior Biologic Failure Crohn's Disease Patients Already on Every-4-Week Dosing.
Sedano R; Guizzetti L; McDonald C; Jairath V
Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1497-1498.e1. PubMed ID: 32763479
[TBL] [Abstract][Full Text] [Related]
39. Case Report: Infusion-Related Reactions to Intravenous Infliximab and Subcutaneous Ustekinumab in Pediatric Crohn's Disease.
Kakiuchi T; Kimura S; Esaki M; Matsuo M
Front Pediatr; 2021; 9():670703. PubMed ID: 35004530
[No Abstract] [Full Text] [Related]
40. Safety Prediction of Infants Born to Mothers with Crohn's Disease Treated with Biological Agents in the Late Gestation Period.
Sako M; Yoshimura N; Sonoda A; Okano S; Ueda M; Tezuka M; Mine M; Yamanishi S; Hashimoto K; Kobayashi K; Takazoe M; Fukata M
J Anus Rectum Colon; 2021; 5(4):426-432. PubMed ID: 34746508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]